We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, EU Likely to Boost Use of Special Designations in 2013: Tufts
FDA, EU Likely to Boost Use of Special Designations in 2013: Tufts
January 11, 2013
U.S. and EU regulators hope to increase the use of special designations, such as fast track, priority review and accelerated approval, to speed approvals of drugs for non-cancer diseases that are rare and/or life-threatening, according to a new Tufts report.